Reported results
- License agreement revenue was $3,117 thousand for the three months ended September 30, 2026, compared to $0 for the three months ended September 30, 2025.
- Research and development expenses were $34.3 million for the three months ended September 30, 2026, compared to $20.3 million for the three months ended September 30, 2025.
- General and administrative expenses were $8.7 million for the three months ended September 30, 2026, compared to $5.5 million for the three months ended September 30, 2025.
- Net loss was $37.7 million, or $0.90 per basic and diluted share, for the three months ended September 30, 2026, compared to $24.6 million, or $1.27 per basic and diluted share, for the three months ended September 30, 2025.
- Cash and cash equivalents were $289.4 million as of September 30, 2026.
Guidance
- Crescent expects that its existing cash and cash equivalents will fund operations into the second half of 2028.
Price and volatility reaction
The stock moved -1.5% on the print. No front-expiry chain was on file, so there is no straddle expected move.
| Measure | Value | Basis |
|---|---|---|
| Close before release | 14.37 | 2026-11-12 |
| Close after release | 14.15 | 2026-11-13 |
| Realised move | -1.5% | close to close |
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-12 (8-K, Item 2.02). Read the original filing on sec.gov.
